Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-04-2019 | Epidemiology

Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011

Authors: Judith Malmgren, Marc Hurlbert, Mary Atwood, Henry G. Kaplan

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

Distant relapse metastatic breast cancer (rMBC) incidence and survival are vital measures of breast cancer diagnosis and treatment progress over time.

Methods

We conducted a retrospective cohort study of stage I–III invasive breast cancer, 1990–2011, follow-up through 2016 [N = 8292, rMBC = 964 (12%)] at a community-based institution. Patient and tumor characteristics (treatment, distant recurrence, vital status) from BC registry data were evaluated. Survival analysis and Cox proportional hazards (HzR) with 95% confidence intervals (95% CI) were calculated using distant recurrence and distant disease-specific survival (DDSS) endpoints.

Results

Both 5- and 10-year distant relapse (rMBC) declined over time from 1990–1998 to 2005–2011 [11% to 5%, 16% to 8% (p < 0.001)]. Proportionately, HER2 + BC distant relapse decreased 9% and triple negative (HR−/HER2−) increased 8% (p = 0.011). In the Cox model, lower stage [stage I: HzR = 0.08 (0.07, 0.10), stage II: 0.29 (0.25, 0.33)], more recent diagnosis years [1999–2004: HzR = 0.60 (0.51, 0.70), 2005–2011: HzR = 0.44 (0.38, 0.52)], HR+ [HzR = 0.62 (0.53, 0.72)], and age 40+ [HzR = 0.81 (0.67, 0.98)] had decreased rMBC risk. Compared to HR+/HER2− BC, triple-negative BC had increased rMBC risk [HzR = 2.02 (1.61, 2.53)] but HER2+ subtypes did not. HR−, age 70+, > 1, or visceral metastases and stage III disease were associated with worse DDSS. DDSS did not improve over time.

Conclusion

rMBC incidence declined over time with decreased HER2-positive distant recurrence, a shift to more triple-negative BC and consistently poor distant disease survival.

DeSantis CE, Ma J, Sauer AG et al (2017) Breast Cancer Statistics, 2017, Racial Disparity in Mortality by State. CA Cancer J Clin 67:439–448. https://doi.org/10.3322/caac.21412 CrossRefPubMed

Siegel RL, Miller KD, Jemal A. (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Mariotto AB, Etzioni R, Hurlbert M et al (2017) Estimation of the number of women living with breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815. https://doi.org/10.1158/1055-9965.EPI-16-0889 CrossRefPubMedPubMedCentral

Malmgren JA, Mayer M, Atwood MK et al (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 167(2):579–590. https://doi.org/10.1007/s10549-017-4529-5 CrossRefPubMed

Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving?. Cancer 100(1):44–52. https://doi.org/10.1002/cncr.11859 CrossRefPubMed

Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 105(8):1742–1750. https://doi.org/10.1002/cncr21359 CrossRef

Tevaarwerk AJ, Gray RJ, Schneider BP et al (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119(6):1140–1148. https://doi.org/10.1002/cncr.27819 CrossRefPubMed

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2009) American Joint Committee on Cancer Staging Manual, 7th edn. Springer, New York

Weeks L (1999) Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network Oncology (Willeston Park) 13(5A):69–71

10.

Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, contract No. N01-CN-67009. Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, Bethesda MD

11.

12.

Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ et al (2012) Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 21(5):800–809. https://doi.org/10.1158/1055-9965.EPI-11-1089 CrossRefPubMed

13.

IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA)

14.

Wu X, Ye Y, Barcenas CH, Chow W-H et al (2017) Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. J Natl Cancer Inst 109(7):djw314. https://doi.org/10.1093/jnci/djw314 CrossRefPubMedCentral

15.

Cossetti RJD, Tyldesley SK, Speers CH et al (2015) Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 33(1):65–73. https://doi.org/10.1200/JCO.2014.57.2461 CrossRefPubMed

16.

Chen L, Romond D, Chokshi S et al (2012) A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease at initial presentation. Breast Cancer Res Treat 136(2):565–572. https://doi.org/10.1007/s10549-012-2265-4 CrossRefPubMed

17.

Rondeau V, Mathoulin-Pelissier S, Tanneau L et al (2010) Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death. BMC Cancer 10:697. https://doi.org/10.1186/1471-2407-10-697 CrossRefPubMedPubMedCentral

18.

Geurtz YM, Witteveen A, Bretvals R et al (2017) Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat 165(3):709–720. https://doi.org/10.1007/s10549-017-4340-3 CrossRef

19.

Tchou J, Greshock J, Bergey MR et al (2008) Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancer. Clin Breast Cancer 8(2):143–148. https://doi.org/10.3816/CBC.2008.n.014 CrossRefPubMed

20.

Joensuu H, Lehtimaki T, Holli K et al (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292(9):1064–1073. https://doi.org/10.1001/jama.292.9.1064 CrossRefPubMed

21.

Kast K, Link T, Petzoid A et al (2015) Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat 150(3):621–629. https://doi.org/10.1007/s10549-015-3341-3 CrossRefPubMed

22.

Early Breast Cancer Trialists Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer in recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0 CrossRef

23.

Gray R, Bradley R, Braybrooke J et al for the EBCTCG. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomized trials. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS1-01. Early Breast Cancer Trialists Collaborative Group (EBCTCG). (Abstract)

24.

Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752. https://doi.org/10.1200/JCO.2014.55.5730 CrossRefPubMedPubMedCentral

25.

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 381(9869):805–816. https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentral

26.

Zhang B, Hurvitz S (2016) Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clin Adv Hematol Oncol 14(7):520–530PubMed

27.

Howlader N, Cronin KA, Kurian AW et al (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 27(6):619–626. https://doi.org/10.1158/1055.9965.EPI-17-0627 CrossRefPubMed

28.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22CrossRefPubMed

29.

Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303 CrossRefPubMed

30.

Colleoni M, Sun Z, Price KN et al (2016) Annual hazard rates of recurrence for breast cancer during 2 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol 34(9):927–935. https://doi.org/10.1200/JCO.2015.62.3504 CrossRefPubMedPubMedCentral

31.

Ellis L, Canchola AJ, Spiegel D et al (2017) Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol 36(1):25–33. https://doi.org/10.1200/JCO.2017.74.2049 CrossRefPubMedPubMedCentral

32.

Plevritis SK, Munoz D, Kurian AW et al (2018) Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012. JAMA 319(2):154–164. https://doi.org/10.1001/jama.2017.19130 CrossRefPubMedPubMedCentral

33.

Malmgren JA, Atwood MK, Kaplan HG (2008) Increase in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990–2005. BMC Cancer 8:131. https://doi.org/10.1186/1471-2407-8-131 CrossRefPubMedPubMedCentral

34.

Anampa J, Sparano JA (2017) New agents for the management of resistant metastatic breast cancer. Expert Opin Pharmacother 18(17):1815–1831. https://doi.org/10.1080/14656566.2017.1409206 CrossRefPubMed

35.

Zardavas D, Maetens M, Irrthum A et al (2014) The AURORA initiative for metastatic breast cancer. Br J Cancer 111(10):1881–1887. https://doi.org/10.1038/bjc.2014.341 CrossRefPubMedPubMedCentral

36.

Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709 CrossRefPubMed

37.

Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638–3646. https://doi.org/10.1200/JCO.2017.75.6155 CrossRefPubMed

38.

Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533. https://doi.org/10.1056/NEJMoa1706450 CrossRefPubMed

Title: Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011
Authors: Judith Malmgren
Marc Hurlbert
Mary Atwood
Henry G. Kaplan
Publication date: 01-04-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-05090-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy

Ectopic breast tissue and cancer

Clinical findings and outcomes of MRI staging of breast cancer in a diverse population

Peer support interventions for breast cancer patients: a systematic review

Identifying adherence barriers to oral endocrine therapy among breast cancer survivors

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer